Loading...
Merck & Co., Inc.
MRK•NYSE
Healthcare
Drug Manufacturers - General
$79.29
$1.17(1.50%)
Merck & Co., Inc. (MRK) Financial Performance & Income Statement Overview
Review Merck & Co., Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
6.74%
↑ 6.74%
Operating Income Growth
668.18%
↑ 668.18%
Net Income Growth
4589.59%
↑ 4589.59%
Operating Cash Flow Growth
65.06%
↑ 65.06%
Operating Margin
31.91%
↑ 31.91%
Gross Margin
76.42%
↑ 76.42%
Net Profit Margin
27.27%
↑ 27.27%
ROE
38.16%
↑ 38.16%
ROIC
22.68%
↑ 22.68%
Merck & Co., Inc. (MRK) Income Statement & Financial Overview
Review Merck & Co., Inc.'s (MRK) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $8.63B | $13.24B | $14.59B | $11.30B |
| Short Term Investments | $599.00M | $447.00M | $0.00 | $50.00M |
| Cash & Short Term Investments | $9.23B | $13.69B | $14.59B | $11.35B |
| Net Receivables | $10.79B | $10.28B | $11.38B | $11.64B |
| Inventory | $6.20B | $6.11B | $6.24B | $6.47B |
| Other Current Assets | $9.29B | $8.71B | $8.14B | $8.74B |
| Total Current Assets | $35.50B | $38.78B | $40.36B | $38.20B |
| Property Plant & Equipment (Net) | $24.79B | $23.78B | $23.45B | $23.22B |
| Goodwill | $21.68B | $21.67B | $21.70B | $21.16B |
| Intangible Assets | $15.76B | $16.37B | $17.01B | $16.98B |
| Goodwill & Intangible Assets | $37.44B | $38.04B | $38.71B | $38.15B |
| Long Term Investments | $616.00M | $463.00M | $575.00M | $357.00M |
| Tax Assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Assets | $16.77B | $16.04B | $14.44B | $12.70B |
| Total Non-Current Assets | $79.62B | $78.32B | $77.17B | $74.42B |
| Total Assets | $115.12B | $117.11B | $117.53B | $112.63B |
| Account Payables | $3.78B | $4.08B | $3.59B | $3.52B |
| Short Term Debt | $1.36B | $2.65B | $3.15B | $3.07B |
| Tax Payables | $5.18B | $3.91B | $4.33B | $2.78B |
| Deferred Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Current Liabilities | $14.85B | $17.78B | $18.52B | $16.69B |
| Total Current Liabilities | $25.17B | $28.42B | $29.59B | $26.06B |
| Long Term Debt | $33.48B | $34.46B | $34.98B | $34.72B |
| Deferred Revenue Non-Current | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred Tax Liabilities Non-Current | $1.41B | $1.39B | $864.00M | $876.00M |
| Other Non-Current Liabilities | $6.66B | $6.46B | $7.54B | $7.33B |
| Total Non-Current Liabilities | $41.55B | $42.31B | $43.39B | $42.92B |
| Capital Lease Obligations | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $66.72B | $70.73B | $72.97B | $68.98B |
| Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock | $1.79B | $1.79B | $1.79B | $1.79B |
| Retained Earnings | $66.10B | $63.07B | $61.38B | $60.19B |
| Accumulated Other Comprehensive Income/Loss | -$4.96B | -$4.95B | -$5.37B | -$5.36B |
| Total Stockholders Equity | $48.34B | $46.31B | $44.50B | $43.58B |
| Total Equity | $48.40B | $46.37B | $44.56B | $43.65B |
| Total Liabilities & Stockholders Equity | $115.12B | $117.11B | $117.53B | $112.63B |
| Total Investments | $1.22B | $910.00M | $575.00M | $407.00M |
| Total Debt | $34.84B | $37.11B | $38.13B | $37.79B |
| Net Debt | $26.21B | $23.87B | $23.54B | $26.48B |
Merck & Co., Inc. (MRK) Balance Sheet Analysis
Merck & Co., Inc. (MRK) manages its money wisely, with plenty of 65.06% and 4589.59% to cover its bills. The company’s long-term debts are manageable, balanced by steady 27.27%. Shareholders’ stake in the business has grown thanks to smart decisions. Overall, the numbers show a solid position, giving it room to invest, expand, or adapt. For investors, this paints a promising picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan